Objective: To report the results of fetal cystoscopic laser ablation of posterior urethral valves (PUV) in a consecutive series in two referral centers. Methods: Twenty pregnant women with a presumptive isolated PUV were treated with fetal cystoscopy under local anesthesia. Identification and fulguration of the PUV by one or several firing-contacts with diode laser were attempted. Perinatal and long-term outcomes were prospectively recorded. Results: The median gestational age at procedure was 18.1 weeks (range 15.0-25.6), and median operation time was 24 min (range 15-40). Access to the urethra was achieved in 19/20 (95%) cases, and postoperative, normalization of bladder size and amniotic fluid was observed in 16/20 (80%). Overall, there were 9 (45%) terminations of pregnancy and 11 women (55%) delivered a liveborn baby at a mean gestational age of 37.3 (29.1-40.2) weeks. No infants developed pulmonary hypoplasia and all were alive at 15-110 months. Eight (40% of all fetuses, 72.7% of newborns) had normal renal function and 3 (27.3%) had renal failure awaiting renal transplantation. Conclusion: Fetoscopic laser ablation for PUV can achieve bladder decompression and amniotic fluid normalization with a single procedure in selected cases with anyhydramnios. There is still a significant risk of progression to renal failure pre or postnatally.

Keywords:
Fetal therapy, Fetal cystoscopy, Fetoscopy, Lower urinary tract obstruction, Posterior urethral valves, Prenatal diagnosis
1.
Robyr R, Benachi A, Daikha-Dahmane F, et al: Correlation between ultrasound and anatomical findings in fetuses with lower urinary tract obstruction in the first half of pregnancy. Ultrasound Obstet Gynecol 2005;25:478-482.
2.
Kaefer M, Peters CA, Retik AB, et al: Increased renal echogenicity: a sonographic sign for differentiating between obstructive and nonobstructive etiologies of in utero bladder distension. J Urol 1997;158:1026-1029.
3.
McHugo J, Whittle M: Enlarged fetal bladders: aetiology, management and outcome. Prenat Diagn 2001;21:958-963.
4.
Abbott JF, Levine D, Wapner R: Posterior urethral valves: inaccuracy of prenatal diagnosis. Fetal Diagn Ther 1998;13:179-183.
5.
Anumba DO, Scott JE, Plant ND, et al: Diagnosis and outcome of fetal lower urinary tract obstruction in the northern region of England. Prenat Diagn 2005;25:7-13.
6.
Merrill DC, Weiner CP: Urinary tract obstruction; in Fisk NM, Moise KJ Jr (eds): Fetal therapy: invasive and transplacental. Cambridge, UK, Cambridge University Press, 1997, pp 273-286.
7.
Johnson MP, Freedman AL: Fetal uropathy. Curr Opin Obstet Gynecol 1999;11:185-194.
8.
Freedman AL, Bukowski TP, Smith CA, Evans MI, Johnson MP, Gonzalez R: Fetal therapy for obstructive uropathy: diagnosis specific outcomes. J Urol 1996;156:720-723; discussion 723-724.
9.
Gonzalez R, De Filippo R, Jednak R, Spencer Barthold J: Urethral atresia: long-term outcome in 6 children who survived the neonatal period. J Urol 2001;165:2241-2244.
10.
Berkowitz R, Glickmann M, Smith G, et al: Fetal urinary tract obstruction: what is the role of surgical intervention in utero? Am J Obstet Gynecol 1982;144:367-375.
11.
Harrison MR, Ross NA, Noall RA: Correction of congenital hydronephrosis in utero I. The model: fetal urethral obstruction produces hydronephrosis and pulmonary hypoplasia in fetal lambs. J Pediatr Surg 1982;17:965-973.
12.
Harrison MR, Nakayama DK, Noall RA, et al: Correction of congenital hydronephrosis in utero II: decompression reverses the effects of obstruction on the fetal lung and urinary tract. J Pediatr Surg 1983;18:247-254.
13.
Golbus MS, Harrison MR, Filly RA, et al: In utero treatment of urinary tract obstruction. Am J Obstet Gynecol 1982;142:383-388.
14.
Coplen DE: Prenatal intervention for hydronephrosis. J Urol 1997;157:2270-2277.
15.
Clark TJ, Martin WL, Divakaran TG, et al: Prenatal bladder drainage in the management of fetal lower urinary tract obstruction: a systematic review and meta-analysis. Obstet Gynecol 2003;102:367-382.
16.
Morris RK, Malin GL, Quinlan-Jones E, et al; Percutaneous vesicoamniotic shunting in Lower Urinary Tract Obstruction (PLUTO) Collaborative Group: Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO): a randomised trial. Lancet 2013;382:1496-1506.
17.
Quintero RA, Johnson MP, Romero R, et al: In-utero percutaneous cystoscopy in the management of fetal lower obstructive uropathy. Lancet 1995;346:537-540.
18.
Quintero RA, Hume R, Smith C, et al: Percutaneous fetal cystoscopy and endoscopic fulguration of posterior urethral valves. Am J Obstet Gynecol 1995;172:206-209.
19.
Quintero R, Johnson M, Muñoz H, et al: In utero endoscopic treatment of posterior urethral valves. Prenatal and Neonatal Medicine 1998;3:208-216.
20.
Welsh A, Agarwal S, Kumar S, et al: Fetal cystoscopy in the management of fetal obstructive uropathy: experience in a single European centre. Prenat Diagn 2003;23:1033-1041.
21.
Agarwal SK, Fisk NM: In utero therapy for lower urinary tract obstruction. Prenat Diagn 2001;21:970-976.
22.
Ruano R, Duarte S, Bunduki V, Giron AM, Srougi M, Zugaib M: Fetal cystoscopy for severe lower urinary tract obstruction: initial experience of a single center. Prenat Diagn 2010;30:30-39.
23.
Morris RK, Ruano R, Kilby MD: Effectiveness of fetal cystoscopy as a diagnostic and therapeutic intervention for lower urinary tract obstruction: a systematic review. Ultrasound Obstet Gynecol 2011;37:629-637.
24.
Nicolaides KH, Cheng HH, Abbas A, et al: Fetal renal defects: associated malformations and chromosomal defects. Fetal Diagn Ther 1992;7:1-11.
25.
Morris RK, Quinlan-Jones E, Kilby MD, Khan KS: Systematic review of accuracy of fetal urine analysis to predict poor postnatal renal function in cases of congenital urinary tract obstruction. Prenat Diagn 2007;27:900-911.
26.
Mahoney BS, Callen PW, Filly RA: Fetal urethral obstruction: US evaluation. Radiology 1985;157:221-224.
27.
Oliveira EA, Rabelo EA, Pereira AK, et al: Prognostic factors in prenatally-detected posterior urethral valves: a multivariate analysis. Pediatr Surg Int 2002;18:662-667.
28.
Estroff JA, Mandell J, Benacerraf BR: Increased renal parenchymal echogenicity in the fetus: importance and clinical outcome. Radiology 1991;181:135-139.
29.
Crombleholme TM, Harrison MR, Golbus MS, et al: Fetal intervention in obstructive uropathy: prognostic indicators and efficacy of intervention. Am J Obstet Gynecol 1990;162:1239-1244.
30.
Morris R, Malin G, Khan K, Kilby M: Antenatal ultrasound to predict postnatal renal function in congenital lower urinary tract obstruction: systematic review of test accuracy. BJOG 2009;116:1290-1299.
31.
Heikkila J, Holmberg C, Kyllonen L, Rintala R, Taskinen S: Long-term risk of end stage renal disease in patients with posterior urethral valves. J Urol 2011;186:2392-2396.
32.
Sarhan O, Zaccaria I, Macher MA, et al: Long-term outcome of prenatally detected posterior urethral valves: single center study of 65 cases managed by primary valve ablation. J Urol 2008;179:307-312.
33.
Martinez JM, Castañón M, Gómez O, Prat J, Eixarch E, Bennasar M, Puerto B, Gratacós E: Evaluation of fetal vocal cords to select candidates for successful fetoscopic treatment of congenital high airway obstruction syndrome: preliminary case series. Fetal Diagn Ther 2013;34:77-84.
34.
Martinez JM, Prat J, Gómez O, Crispi F, Bennasar M, Puerto B, Castañón M, Gratacós E: Decompression through tracheobronchial endoscopy of bronchial atresia presenting as massive pulmonary tumor: a new indication for fetoscopic surgery. Fetal Diagn Ther 2013;33:69-74.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.